≡

ELISA Kit for Versican (VCAN)

CSPG2; VS; ERVR; PG-M; WGN1; Chondroitin Sulfate Proteoglycan 2; Chondroitin sulfate proteoglycan core protein 2; Glial hyaluronate-binding; Large fibroblast proteoglycan

Specificity

This assay has high sensitivity and excellent specificity for detection of Versican (VCAN).
No significant cross-reactivity or interference between Versican (VCAN) and analogues was observed.

Recovery

Matrices listed below were spiked with certain level of recombinant Versican (VCAN) and the recovery rates were calculated by comparing the measured value to the expected amount of Versican (VCAN) in samples.

Matrix Recovery range (%) Average(%)
serum(n=5) 97-105 101
EDTA plasma(n=5) 79-97 91
heparin plasma(n=5) 80-101 89

Precision

Intra-assay Precision (Precision within an assay): 3 samples with low, middle and high level Versican (VCAN) were tested 20 times on one plate, respectively.
Inter-assay Precision (Precision between assays): 3 samples with low, middle and high level Versican (VCAN) were tested on 3 different plates, 8 replicates in each plate.
CV(%) = SD/meanX100
Intra-Assay: CV<10%
Inter-Assay: CV<12%

Linearity

The linearity of the kit was assayed by testing samples spiked with appropriate concentration of Versican (VCAN) and their serial dilutions. The results were demonstrated by the percentage of calculated concentration to the expected.

Sample 1:2 1:4 1:8 1:16
serum(n=5) 86-97% 80-101% 80-92% 78-99%
EDTA plasma(n=5) 83-99% 94-101% 96-105% 85-101%
heparin plasma(n=5) 93-102% 81-101% 83-97% 90-98%

Stability

The stability of kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition.
To minimize extra influence on the performance, operation procedures and lab conditions, especially room temperature, air humidity, incubator temperature should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same operator from the beginning to the end.

Reagents and materials provided

Reagents Quantity Reagents Quantity
Pre-coated, ready to use 96-well strip plate 1 Plate sealer for 96 wells 4
Standard 2 Standard Diluent 1×20mL
Detection Reagent A 1×120µL Assay Diluent A 1×12mL
Detection Reagent B 1×120µL Assay Diluent B 1×12mL
TMB Substrate 1×9mL Stop Solution 1×6mL
Wash Buffer (30 × concentrate) 1×20mL Instruction manual 1

Assay procedure summary

1. Prepare all reagents, samples and standards;
2. Add 100µL standard or sample to each well. Incubate 1 hours at 37°C;
3. Aspirate and add 100µL prepared Detection Reagent A. Incubate 1 hour at 37°C;
4. Aspirate and wash 3 times;
5. Add 100µL prepared Detection Reagent B. Incubate 30 minutes at 37°C;
6. Aspirate and wash 5 times;
7. Add 90µL Substrate Solution. Incubate 10-20 minutes at 37°C;
8. Add 50µL Stop Solution. Read at 450nm immediately.

GIVEAWAYS

INCREMENT SERVICES

Magazine Citations
Plos one Tumor-Produced Versican V1 Enhances hCAP18/LL-37 Expression in Macrophages through Activation of TLR2 and Vitamin D3 Signaling to Promote Ovarian Cancer Progression In Vitro PubMed: PMC3570526
Clinica Chimica Acta Versican and its associated molecules: Potential diagnostic markers for multiple myeloma Pubmed:25623955
Journal of Cancer Research and Clinical Oncology Clinical significance of circulatory microRNA-203 in serum as novel potential diagnostic marker for multiple myeloma
RNA Biology Targeting of stromal versican by miR-144/199 inhibits multiple myeloma by downregulating FAK/STAT3 signaling Pubmed: 31532704
miR-124-3p and miR-181a-5p Mediate AT1-Receptor Autoantibody Induced Fetal Rat Cardiac Remodeling via Increased VCAN Expression
Catalog No. Related products for research use of Rattus norvegicus (Rat) Organism species Applications (RESEARCH USE ONLY!)
RPB817Ra01 Recombinant Versican (VCAN) Positive Control; Immunogen; SDS-PAGE; WB.
PAB817Ra01 Polyclonal Antibody to Versican (VCAN) WB; IHC; ICC; IP.
SEB817Ra ELISA Kit for Versican (VCAN) Enzyme-linked immunosorbent assay for Antigen Detection.